Beam Therapeutics Price Target Cut to $28.00/Share From $65.00 by Wedbush

What happened

Wedbush cut its price target on Beam Therapeutics to $28 per share from $65.00 while keeping an Outperform rating, which means the firm still expects the stock to do better than the broader market.

Confirmed

Global impact / market context

A lower price target means Wedbush expects less upside than before, which can prompt investors to reset what they are willing to pay for Beam shares and may reduce demand from buyers who rely on analyst targets.

Analyst inference

Keeping Outperform while halving the target suggests Wedbush still likes the company but is less optimistic about how much it is worth, a split signal for investors weighing the stock.

Analyst inference

What to watch

1. Whether other analysts also change their price targets or ratings on Beam Therapeutics, which would show if Wedbush's cut reflects a broader view. Confirmed
2. Watch for any company announcements on spending plans, trial progress, or cash available, which means the money on hand, since these could support or challenge the lower target. Proposed
3. Track Beam's share price reaction after the cut, because a muted move could mean investors already expected it, while a sharp drop would show surprise. Analyst inference

Evidence

• Original source link unavailable